AR063311A1 - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- AR063311A1 AR063311A1 ARP070104573A ARP070104573A AR063311A1 AR 063311 A1 AR063311 A1 AR 063311A1 AR P070104573 A ARP070104573 A AR P070104573A AR P070104573 A ARP070104573 A AR P070104573A AR 063311 A1 AR063311 A1 AR 063311A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- lower alkyl
- hydrogen
- formula
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- -1 thiocarbamoyl group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003003 spiro group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 abstract 1
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000000320 amidine group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82998006P | 2006-10-18 | 2006-10-18 | |
| US95234107P | 2007-07-27 | 2007-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063311A1 true AR063311A1 (es) | 2009-01-21 |
Family
ID=39276877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104573A AR063311A1 (es) | 2006-10-18 | 2007-10-16 | Compuestos organicos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8222248B2 (enExample) |
| EP (1) | EP2074089B1 (enExample) |
| JP (1) | JP5298022B2 (enExample) |
| KR (1) | KR20090071642A (enExample) |
| AR (1) | AR063311A1 (enExample) |
| AU (1) | AU2007311087B2 (enExample) |
| BR (1) | BRPI0718478A2 (enExample) |
| CA (1) | CA2666880A1 (enExample) |
| CL (1) | CL2007002974A1 (enExample) |
| ES (1) | ES2440253T3 (enExample) |
| MX (1) | MX2009004047A (enExample) |
| PE (1) | PE20080888A1 (enExample) |
| RU (1) | RU2009118489A (enExample) |
| TW (1) | TW200829563A (enExample) |
| WO (1) | WO2008048991A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
| AR058562A1 (es) | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
| MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
| AU2007266796B2 (en) | 2006-05-30 | 2011-02-10 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
| AR069802A1 (es) | 2007-12-20 | 2010-02-17 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores de dgat1 190 |
| WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US20110301192A1 (en) * | 2008-10-01 | 2011-12-08 | The Regents Of The University Of California | Inhibitors of Cyclin Kinase Inhibitor p21 |
| GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| JP2012520887A (ja) * | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| MX2011014018A (es) | 2009-06-19 | 2012-02-22 | Astrazeneca Ab | Pirazincarboxamidas como inhibidores de dgati. |
| EP2456310A4 (en) * | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| KR101194995B1 (ko) * | 2009-10-14 | 2012-10-29 | 주식회사 이큐스앤자루 | 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물 |
| WO2011099832A2 (en) * | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| CA2801274C (en) | 2010-06-01 | 2021-06-15 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
| JP2015506360A (ja) * | 2012-01-06 | 2015-03-02 | ユニバーシティ・オブ・サウス・フロリダ | 組成物、使用方法および処置方法 |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| JP6392352B2 (ja) | 2013-12-19 | 2018-09-19 | ノバルティス アーゲー | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| WO2015166398A1 (en) * | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| CA2986930C (en) | 2015-06-24 | 2023-09-26 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| JP7278945B2 (ja) | 2016-09-20 | 2023-05-22 | サントル レオン ベラール | 抗癌剤としてのベンゾイミダゾール誘導体 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| WO2020023782A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| NZ773110A (en) * | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| WO2020120576A1 (en) * | 2018-12-11 | 2020-06-18 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | p38α AUTOPHOSPHORYLATION INHIBITORS |
| TW202116754A (zh) | 2019-07-11 | 2021-05-01 | 美商Ｅ 斯蓋普生物股份有限公司 | 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑 |
| JP2023512116A (ja) * | 2020-01-28 | 2023-03-23 | プロテゴ バイオファーマ， インコーポレイテッド | トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法 |
| EP4143329A4 (en) | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| AU2021263383A1 (en) | 2020-04-29 | 2022-11-24 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| TW202237090A (zh) * | 2020-12-11 | 2022-10-01 | 英商Ｔｍｅｍ16Ａ有限公司 | 治療呼吸道疾病之化合物 |
| MX2023014819A (es) | 2021-06-14 | 2024-03-21 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer. |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| TW202329955A (zh) * | 2022-01-12 | 2023-08-01 | 英屬開曼群島商百濟神州有限公司 | 作為ＤＮＡ聚合酶Ｔｈｅｔａ抑製劑之噻唑并吡啶基醯胺衍生物 |
| EP4265247A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
| CN116253755A (zh) * | 2023-02-28 | 2023-06-13 | 湖南大学 | 一种二芳基硼酸酯类化合物的合成方法 |
| CN117327020B (zh) * | 2023-10-07 | 2026-07-31 | 中国科学院过程工程研究所 | 一种含苯并氮杂环结构的氨基芳香化合物及其制备方法和应用 |
| US11970468B1 (en) | 2023-10-23 | 2024-04-30 | King Faisal University | 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound |
| CN120118037B (zh) * | 2023-12-07 | 2025-11-28 | 南华大学 | 一类含苯甲酸酯结构的苯并咪唑类化合物、制造方法及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3551443A (en) * | 1968-10-30 | 1970-12-29 | Ciba Ltd | 2-phenylbenzoxazole derivatives |
| JPH0678308B2 (ja) * | 1985-04-24 | 1994-10-05 | 三共株式会社 | フタルイミド誘導体およびそれを含有する農園芸用殺菌剤 |
| EP0882718B1 (en) | 1995-12-28 | 2005-08-31 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| EP0963371B1 (en) | 1997-02-25 | 2003-05-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| US6251689B1 (en) * | 1998-05-14 | 2001-06-26 | Telik, Inc. | Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| HK1047582B (zh) * | 1999-06-23 | 2005-03-04 | 萨诺费－阿文蒂斯德国有限公司 | 取代的苯並咪唑 |
| EP1210336B1 (en) | 1999-08-26 | 2007-04-25 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| DE60115265T2 (de) * | 2000-09-19 | 2006-08-10 | Lee, Moses, Holland | Zusammensetzungen und verfahren zur verwendung achiraler analoge von cc-1065 und den duocarmycinen |
| JP2004515496A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| FR2821721B1 (fr) * | 2001-03-08 | 2004-07-09 | Laurent Locatelli | Composition pour alimentation animale, utilisation de cette composition, et produit pour alimentation animale comprenant cette composition |
| BR0208010A (pt) * | 2001-03-12 | 2004-12-21 | Avanir Pharmaceuticals | Composto de benzimidazol para modulação de ige e inibição de proliferação celular |
| JP4637481B2 (ja) * | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| EP1455815A4 (en) | 2001-12-19 | 2006-11-02 | Millennium Pharm Inc | MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| WO2003106439A1 (ja) * | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬 |
| US20060293256A1 (en) * | 2002-08-06 | 2006-12-28 | Masateru Yamada | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| JP2006516254A (ja) | 2003-01-06 | 2006-06-29 | イーライ・リリー・アンド・カンパニー | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AR044399A1 (es) | 2003-05-20 | 2005-09-14 | Novartis Ag | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
| WO2005108370A1 (ja) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| AU2005295453A1 (en) * | 2004-10-15 | 2006-04-27 | Bayer Healthcare Llc | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| JP2009001495A (ja) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体 |
| US8629147B2 (en) * | 2005-11-03 | 2014-01-14 | Chembridge Corporation | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| BRPI0707719A2 (pt) * | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo |
-
2007
- 2007-10-16 PE PE2007001396A patent/PE20080888A1/es not_active Application Discontinuation
- 2007-10-16 AR ARP070104573A patent/AR063311A1/es not_active Application Discontinuation
- 2007-10-17 MX MX2009004047A patent/MX2009004047A/es not_active Application Discontinuation
- 2007-10-17 CL CL200702974A patent/CL2007002974A1/es unknown
- 2007-10-17 JP JP2009533499A patent/JP5298022B2/ja not_active Expired - Fee Related
- 2007-10-17 CA CA002666880A patent/CA2666880A1/en not_active Abandoned
- 2007-10-17 AU AU2007311087A patent/AU2007311087B2/en not_active Ceased
- 2007-10-17 BR BRPI0718478-6A2A patent/BRPI0718478A2/pt not_active IP Right Cessation
- 2007-10-17 RU RU2009118489/04A patent/RU2009118489A/ru not_active Application Discontinuation
- 2007-10-17 ES ES07854118.2T patent/ES2440253T3/es active Active
- 2007-10-17 KR KR1020097010003A patent/KR20090071642A/ko not_active Withdrawn
- 2007-10-17 US US12/446,088 patent/US8222248B2/en not_active Expired - Fee Related
- 2007-10-17 TW TW096138922A patent/TW200829563A/zh unknown
- 2007-10-17 EP EP07854118.2A patent/EP2074089B1/en not_active Not-in-force
- 2007-10-17 WO PCT/US2007/081607 patent/WO2008048991A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090071642A (ko) | 2009-07-01 |
| BRPI0718478A2 (pt) | 2013-11-26 |
| AU2007311087B2 (en) | 2012-03-01 |
| US20110046133A1 (en) | 2011-02-24 |
| RU2009118489A (ru) | 2010-11-27 |
| TW200829563A (en) | 2008-07-16 |
| WO2008048991A2 (en) | 2008-04-24 |
| ES2440253T3 (es) | 2014-01-28 |
| EP2074089A2 (en) | 2009-07-01 |
| PE20080888A1 (es) | 2008-08-26 |
| EP2074089B1 (en) | 2013-09-18 |
| JP5298022B2 (ja) | 2013-09-25 |
| MX2009004047A (es) | 2009-07-21 |
| CL2007002974A1 (es) | 2008-05-23 |
| WO2008048991A3 (en) | 2008-07-10 |
| JP2010506950A (ja) | 2010-03-04 |
| CA2666880A1 (en) | 2008-04-28 |
| US8222248B2 (en) | 2012-07-17 |
| AU2007311087A1 (en) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
| ES2512491T3 (es) | Derivados de la piridina pirazolo como inhibidores de la NADPH oxidasa | |
| AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
| NI201900029A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| AR072839A1 (es) | Derivados adamantil diamida y usos de los mismos | |
| AR085425A1 (es) | Inhibidores de la glucosilceramida sintasa | |
| AR055959A1 (es) | Derivados espiro para la modulacion de actividad de crth2 | |
| AR064491A1 (es) | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR043674A1 (es) | Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa | |
| AR040476A1 (es) | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| CO6230982A2 (es) | Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen | |
| AR038562A1 (es) | 2-amino-4-biciclilamino-6h-1,3,5,-triazinas,procedimiento para su preparacion y su empleo como herbicidas y reguladores de crecimiento de plantas | |
| ECSP088129A (es) | Derivado novedoso de heterocicliden acetamida | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| CU20080165A7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR086086A1 (es) | Derivados glucosidos y usos de los mismos | |
| JP2010506950A5 (enExample) | ||
| AR050194A1 (es) | Analogos de biaril piperazinil-piridina sustituidos | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |